|
The Correlation of TGF-ß Level and GARP Gene Expression in Iraqi Patients with Rheumatoid Arthritis Treated By Biological and Chemo-Therapy
|
|
| Author:
|
SHAWQ RAAFAT MOHAMMED, ZAINAB THAMER SHOWAIT AL-ASADY, MOHAMMED MAHDI JAWAD, MOHAMMED H. ALOSAMI
|
| Abstract:
|
GARP is a leucine rich repeat family member that play role in mediating the surface expression of TGF-ß in regulatory T cells, TGF-ß is one of anti-inflammatory cytokines that plays role in inhibits T effector proliferation and differentiation in autoimmune disease. The study aims to estimate the level of TGF-ß1 and gene expression of LRRC32 gene (GARP) in Iraqi patients with Rheumatoid arthritis treated by biological and chemotherapy. lood samples were collected from 30 patients diagnosed with Rheumatoid arthritis (RA) and 24 healthy donors as control group to measure the level of TGF-ß1 by ELISA and the gene expression of LRRC32 (GARP gene) by RT-qPCR technique. Rheumatoid arthritis patients showed a significant decrease in the TGF-ß1 level in the serum of RA patients that treated with biological therapy compared to other type of treatments as well as to control group. A significant increase was detected in the folding of gene expression of LRRC32 gene in RA patients treated with biological therapy and others that treated with biological and chemotherapy compared to control group. Although, high effectiveness of Treg cells in patients with RA under biological and chemotherapy through the increase the folding of LRRC32 gene expression, the results of current study showed there was decrease in the TGF-ß level in patients with RA under biological therapy because the inhibition of pro-inflammatory factors, including TNF-a that affects the efficacy of the effector cells, including Th and Treg that may reflect on TGF-ß level production from Treg.
|
| Keyword:
|
rheumatoid arthritis, LRRC32 gene, GARP, TGF-ß1, Biological therapy.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.SP1.240
|
| Download:
|
Request For Article
|
|
|